Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series

Crit Care. 2020 Jul 3;24(1):392. doi: 10.1186/s13054-020-03078-z.

Authors

Kent Doi¹, Mahoko Ikeda², Naoki Hayase³, Kyoji Moriya^{2

4}, Naoto Morimura³; COVID-UTH Study Group

Collaborators

Affiliations

¹ Department of Acute Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan. kdoi-tky@umin.ac.jp.
² Department of Infection Control and Prevention, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
³ Department of Acute Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
⁴ Department of Infectious Diseases, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.

No abstract available

Publication types

Letter

MeSH terms

Aged
Amides / therapeutic use*
Benzamidines
COVID-19 Drug Treatment
Coronavirus Infections / drug therapy
Critical Illness
Drug Therapy, Combination
Female
Guanidines / therapeutic use*
Humans
Male
Middle Aged
Pyrazines / therapeutic use*
Treatment Outcome

Substances

Amides
Benzamidines
Guanidines
Pyrazines
favipiravir
nafamostat